Presented by Prime Oncology - Oncoletter, Webportal für Onkologie und onkologische Hämatologie mit integrierten Links zu Wikipedia und Pharma Wiki sowie NCI, Kompendium, Medline und wichtigen Kongressen wie ASCO, ASH, SABCS, ESMO, EHA, Darmkrebs, Nierenkrebs, Brustkrebs, Prostatakrebs

Startseite

Kongressberichte & Archiv

Archiv 2017

ESMO 19th World Congress on Gastrointestinal Cancer

Cancer of the Pancreas

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

Symposiumsbericht

TEXT

Welcome and introduction

Michel Ducreux, MD, PhD

SLIDES

Case 1—Metastatic pancreatic adenocarcinoma: What therapy should I select first?

Marc Peeters, MD, PhD

SLIDES

Case 2—Optimal management of progressive metastatic pancreatic adenocarcinoma: Second-line therapy and beyond

Gerald Prager, MD

SLIDES

Importance of nutrition in pancreatic cancer care

Federico Bozzetti, MD

SLIDES

Future perspectives and prIME Points™

Michel Ducreux, MD, PhD

SLIDES

News

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

26-03-2021 09:58

Go to the ELCC/ESMO 2021 PRESS RELEASE

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

25-03-2021 17:15

Go to the ELCC/ESMO 2021 PRESS RELEASE

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

24-03-2021 09:47

ASCO and the oncology community are deeply saddened by the passing of José Baselga, MD, PhD, FASCO, on March 21, 2021, at age 61. Dr. Baselga died of Creutzfeldt-Jakob disease, a rare fatal neurodegenerative disorder, according to his family. READ MORE

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

22-03-2021 11:06

Read more

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

22-03-2021 10:58

Read more

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

08-02-2021 10:02

Breyanzi demonstrated a 73% overall response rate and 54% complete response (CR) rate in the largest pivotal trial in 3L+ LBCL, TRANSCEND NHL 001 trial MORE INFO

Navigating Treatment Decisions in Metastatic Pancreatic Cancer, Presented by Prime Oncology

News

New Standard of Care: Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Longer Follow-Up Continues to Support First-Line Pembrolizumab Plus Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer

SECOND DRUG TARGETING KRAS G12C SHOWS BENEFIT IN MUTATED NON-SMALL-CELL LUNG CANCER

ASCO Remembers Breast Cancer Drug Development Pioneer Dr. José Baselga

Pembrolizumab + Lenvatinib Significantly Improved PFS & OS vs CT in Advanced Endometrial Cancer Following Prior Platinum-Based CT

Rucaparib Significantly Improves PFS vs Chemotherapy in Later-line Ovarian Cancer with BRCA Mutation

News From the Food and Drug Administration

HOPOS – Erster nationaler Dachverband in der Schweiz/première organisation faîtière de Suisse

U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel), a New CAR T Cell Therapy for Adults with Relapsed or Refractory Large B-cell Lymphoma

Newsletter